SynthesisZeitschrift fur Rheumatologie2025
Diagnostic accuracy of ferritin and glycosylated ferritin in adult-onset Still's disease: a meta-analysis.
Synthesis in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathogenic and genetic landscape of Still's disease across ages, with new insights into age-related IL-18 patterns.Arthritis research & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to ascertain and compare the diagnostic efficacy of ferritin and glycosylated ferritin in adult-onset Still's disease (AOSD).
methodsA thorough meta-analysis was conducted using data extracted from MEDLINE, Embase, and the Cochrane Library. Separate meta-analyses were performed to assess the diagnostic accuracies of ferritin and glycosylated ferritin in patients with AOSD.
resultsEight studies encompassing 556 AOSD patients and 763 non-AOSD controls were included in the analysis. Ferritin cut-off values ranged widely, from 400 to 5000 μg/L, with some studies using a relative threshold, such as ≥ 5 times the normal upper limit. Glycosylated ferritin was reported, with thresholds ranging from 16 to 33%. Ferritin displayed a sensitivity of 60.4% and a specificity of 85.7%, accurately identifying AOSD in 60.4% of cases and accurately excluding non-AOSD in 85.7% of cases. The sensitivity in ferritin-specific studies escalated to 66.8%, while specificity was maintained at 84.7%. Glycosylated ferritin exhibited a higher sensitivity of 74% and a slightly lower specificity of 80.5%, indicating superior detection of AOSD cases. The positive likelihood ratio (PLR) and negative likelihood ratio (NLR) for ferritin were 4.179 and 0.399, respectively; for glycosylated ferritin alone, these values were 3.604 and 0.357, demonstrating moderate diagnostic reliability. Diagnostic odds ratios (DORs) were 11.32 for ferritin and 10.14 for glycosylated ferritin. The area under the curve (AUC) was 0.778 for ferritin and 0.835 in ferritin-specific studies, indicating moderate diagnostic precision. The AUC for glycosylated ferritin was not available. The Q* index was 0.717 for ferritin and 0.768 for the ferritin-only group, reflecting a slight improvement when focusing exclusively on ferritin.
conclusionBoth ferritin and glycosylated ferritin serve as valuable markers for diagnosing AOSD, with ferritin demonstrating superior sensitivity and specificity in targeted studies. Nonetheless, their moderate diagnostic effectiveness suggests that these biomarkers should be used in conjunction with other clinical criteria to ensure a comprehensive diagnosis.
Indexed as
Identifiers
40569435What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.